You are very focused on the contract breach. In m
Post# of 36536
(Total Views: 282)
Posted On: 01/09/2020 10:21:56 AM
Re: homerbedloe #10754
You are very focused on the contract breach. In my mind, it's not just that these bad actors were able to throw wrenches in the works. This is just one piece of the 2019 picture that didn't go as planned.
In the Veneto deal, from my best understanding, GNBT gave full consideration without receiving the most valuable assets of the target company.
Excellagen has yet to show significant revs, despite the hiring of commission-based salespeople and a very low manufacturing cost.
Other parts of the company have not been on the radar (Pantheon, Medisource).
AltuCell was supposed to close by year-end 2019.
NGIO spin was touted for November (the biggest miss, in my opinion, since it could have provided the cash to set the wheels turning).
Uplist not met (should never have been touted as the lead dog in the race, should have been the sled being pulled by the others)
Yes, these things take time, etc. But fact remains that the time frames were set by GNBT, and they were not met.
As stated, we are all still long here, so we still believe the long-term picture. But if NGIO doesn't spin soon, S-1 doesn't come thru without major dilution, Excellagen doesn't get some traction, etc., people will probably start to reconsider.
In the Veneto deal, from my best understanding, GNBT gave full consideration without receiving the most valuable assets of the target company.
Excellagen has yet to show significant revs, despite the hiring of commission-based salespeople and a very low manufacturing cost.
Other parts of the company have not been on the radar (Pantheon, Medisource).
AltuCell was supposed to close by year-end 2019.
NGIO spin was touted for November (the biggest miss, in my opinion, since it could have provided the cash to set the wheels turning).
Uplist not met (should never have been touted as the lead dog in the race, should have been the sled being pulled by the others)
Yes, these things take time, etc. But fact remains that the time frames were set by GNBT, and they were not met.
As stated, we are all still long here, so we still believe the long-term picture. But if NGIO doesn't spin soon, S-1 doesn't come thru without major dilution, Excellagen doesn't get some traction, etc., people will probably start to reconsider.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼